News

Fusion Antibodies, pre-clinical antibody discovery and development experts and BioTickle, their exclusive distributor in India, are providing local biopharmaceutical organisations with access to invaluable unique biopharmaceutical development capabilities. As Dr Richard Jones, CEO of Fusion Antibodies explains, "We are proud...

Cognizant announced it has agreed to acquire TQS Integration, a privately owned global industrial data and intelligence company based in Lismore, Ireland. TQS delivers manufacturing data intelligence, global technology consulting and digital systems integration to help manufacturers accelerate their...

In conjunction with the IAS Conference on HIV Science, Frontier Biotechnologies announced positive top-line results for its phase 3 TALENT study, which demonstrated that an ABT-based two-drug treatment arm was non-inferior to a lopinavir (LPV)-based three-drug arm (75.7% vs...

Thermo Fisher Scientific has expanded its gene therapy portfolio to include a new media panel, gene kit and advanced purification resins to support gene therapy developers seeking to rapidly and efficiently scale adeno-associated viral (AAV) production. AAV, which has become...

Chicago-based biotech development company Sparx Therapeutics has announced ambitious plans to construct a 1,200,00-sq. ft antibody drug manufacturing site in China. The research-based company plans to build the facility east of Shanghai, in Yangzhou, having signed a 20-year lease agreement. So...

On 9 November 2021, the 18th Annual CPhI Pharma Awards will take place in Milan, Italy at the Stella Polare Convention Centre. The CPhI Pharma Awards celebrate innovators and thought leaders breaking new ground in the pharma and biopharma...

UK-based software provider to the life science industry, Veratrak, has announced its partnership with French contract development and manufacturing organisation (CDMO) Skyepharma. Skyepharma is a fully integrated CDMO offering early formulation development, scale up, manufacturing and packaging of classic and...